WINREVAIR (sotatercept-csrk) for injection

WINREVAIR is a prescription medicine used to treat Pulmonary Arterial Hypertension. FDA approved sotatercept-csrk (brand name WINREVAIR) is not (yet) registered or available in India but on request Indian patient can buy WINREVAIR at the lowest price.

Winrevair-sotatercept-Price-Delhi-India
Winrevair (sotatercept) for Injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Winrevair (sotatercept) for Injection

Lazertinib, sold under the brand name Lazcluze among others, is an anti-cancer medication used for the treatment of non-small cell lung cancer.

WINREVAIR is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO group 1) to increase exercise capacity, improve function, and reduce clinical worsening.

In the United States, sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1).

In the European Union, sotatercept, in combination with other pulmonary arterial hypertension therapies, is indicated for the treatment of pulmonary arterial hypertension in adults with WHO Functional Class (FC) II to III, to improve exercise capacity.

The most common side effects include headache, epistaxis (nosebleed), rash, telangiectasia (spider veins), diarrhea, dizziness, and erythema (redness of the skin).

Sotatercept was approved for medical use in the United States in March 2024, and in the European Union in August 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

BLA 761363
Drug Name: Winrevair
Active Ingredient: sotatercept-csrk
Approval Date: 3/26/2024
Dosage form: for Injection
FDA-approved use on approval date: To treat pulmonary arterial hypertension
Company: Merck Sharp & Dohme, LLC

Treatment for: Pulmonary Arterial Hypertension
Dosage Forms And Strengths:
• For injection: 45 mg lyophilized cake or powder in a single-dose vial
• For injection: 60 mg lyophilized cake or powder in a single-dose vial

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.